Glenmark Pharmaceuticals USA launches Clindamycin Phosphate Foam, 1%
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
Approval is based on positive data from the Phase 3 ECHELON-3 trial
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Subscribe To Our Newsletter & Stay Updated